Sarah Trice, PhD, MBA

XtalPi, Massachusetts, United States

Dr. Sarah Trice started her career as a medicinal chemist at Merck & Co. working to discover and develop novel HIV therapies. She later joined Merck KGaA and held a series of leadership positions to support the development and commercialization of enabling technologies for the pharmaceutical industry, notably leading the acquisition and development of SYNTHIA, an AI-powered retrosynthesis SaaS. After completing her MBA from MIT’s Sloan School, Sarah was a co-founder and COO of Entos (now Iambic), a small molecule oncology drug discovery company and the intersection of AI and automation. Sarah currently serves as the COO, Head of US Operations for XtalPi, a technology development company specializing in AI and automation for drug discovery.

Disclosure information not submitted.

Presentation(s):

• Leveraging Intelligent Automation for Enhanced Drug Discovery: Use Cases and Applications

  Wednesday, February 7, 2024
  2:00 PM – 2:30 PM EST